Jincheng Pharmaceutical (300233.SZ) announced on September 23 that on September 20, 2024, Dongfang Lue received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the Phase II clinical trial application for the global first HPV therapeutic vaccine VGX-3100 jointly developed by Dongfang Lue and Inovio Pharmaceuticals, Inc. of usa targeting HPV-16/18-related anal precancerous lesions. The approval of the Phase II clinical trial application for HPV-16/18-related anal precancerous lesions marks another important progress for VGX-3100 after the clinical trial indication of precancerous cervical lesions has been approved.
It is reported that Beijing Dongfang Lve Biomedical Technology Co., Ltd. (referred to as "Dongfang Lue") is a joint venture company of Shanghai Qian De Equity Investment Partnership Enterprise (Limited Partnership), in which Shandong Jincheng Medical Group Co., Ltd. has invested in the shanghai private equity.